AXSM logo

AXSM
Axsome Therapeutics Inc

11,854
Mkt Cap
$9.51B
Volume
527,083.00
52W High
$191.50
52W Low
$96.09
PE Ratio
-50.34
AXSM Fundamentals
Price
$185.96
Prev Close
$182.72
Open
$181.57
50D MA
$170.66
Beta
0.75
Avg. Volume
576,010.96
EPS (Annual)
-$3.68
P/B
107.17
Rev/Employee
$690,265.95
$8,981.00
Loading...
Loading...
News
all
press releases
M&T Bank Corp Acquires 47,602 Shares of Axsome Therapeutics, Inc. $AXSM
M&T Bank Corp lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2,553.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Peregrine Capital Management LLC Trims Position in Axsome Therapeutics, Inc. $AXSM
Peregrine Capital Management LLC lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 27.7% during the 4th quarter, according to its most recent filing with the Securities...
MarketBeat·1d ago
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Insider Sells $1,368,150.00 in Stock
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the firm's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the...
MarketBeat·2d ago
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Passes Above 50-Day Moving Average - Here's Why
Axsome Therapeutics (NASDAQ:AXSM) Shares Pass Above 50 Day Moving Average - Here's Why...
MarketBeat·3d ago
News Placeholder
Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM
Iridian Asset Management LLC CT lowered its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 11.7% during the fourth quarter, according to its most recent Form 13F...
MarketBeat·12d ago
News Placeholder
UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price
UBS Group upped their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·15d ago
News Placeholder
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports...
MarketBeat·15d ago
News Placeholder
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM
Element Squared LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and...
MarketBeat·21d ago
News Placeholder
Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda
(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...
Nasdaq News: Markets·24d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM
Hennion & Walsh Asset Management Inc. cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 18.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,386 shares of the company's stock after selling 8,530 share...
MarketBeat·26d ago
<
1
2
...
>

Latest AXSM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.